Search Result

Results for "

PARP-2/1-IN-2

" in MedChemExpress (MCE) Product Catalog:

By Targets:	PARP (19) Apoptosis (4) Autophagy (1) HDAC (1) Microtubule/Tubulin (1) PI3K (1) Topoisomerase (1)
By Research Areas:	Cancer (19) Neurological Disease (1)

Targets Recommended: PARP AIM2 NEKs

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-12418

Stenoparib 1 Publications Verification E7449; 2X-121	PARP	Cancer
Stenoparib (E7449) is a potent PARP1 and *PARP2* inhibitor and also inhibits TNKS1 and TNKS2, with IC₅₀s of 2.0, 1.0, ∼50 and ∼50 nM for PARP1, PARP2, TNKS1 and TNKS2, respectively, using ³²P-NAD ⁺ as substrate.

HY-13536

AZD-2461 5+ Cited Publications	PARP	Cancer
AZD-2461 is a potent PARP inhibitor, with IC₅₀s of 5 nM, 2 nM and 200 nM for PARP1, PARP2 and PARP3, respectively.

HY-10614

A-966492 3 Publications Verification	PARP	Cancer
A-966492 is a novel and potent inhibitor of PARP1 and PARP2 with K_i of 1 nM and 1.5 nM, respectively.

HY-10130

Veliparib dihydrochloride 30+ Cited Publications ABT-888 dihydrochloride	PARP Autophagy	Cancer
Veliparib (dihydrochloride) is a potent inhibitor of PARP1* and PARP2 with K_is of* 5.2 nM and 2.9 nM in cell-free assays, respectively.

HY-119653

AZ9482	PARP	Cancer
AZ9482 is a triple PARP1/2/6 inhibitor, with IC₅₀ values of 1 nM, 1 nM and 640 nM for PARP1, PARP2 and PARP6, respectively .

HY-10617

Rucaparib phosphate Maximum Cited Publications 38 Publications Verification AG-014699 phosphate; PF-01367338 phosphate	PARP	Cancer
Rucaparib (AG014699) phosphate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib phosphate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib phosphate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617A

Rucaparib Maximum Cited Publications 38 Publications Verification AG014699; PF-01367338	PARP	Cancer
Rucaparib (AG014699) is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib has the potential for castration-resistant prostate cancer (CRPC) research .

HY-105253

*PARP-2/1-IN-2*	PARP	Neurological Disease
PARP-2/1-IN-2 (Compound 4a), the enantiomer of Veliparib (HY-10129), is a potent PARP inhibitor with K_is of 2 and 5 nM against *PARP-2* and PARP-1, respectively. PARP-2/1-IN-2 has an EC₅₀ of 3 nM in a cell based assay of PARP activity .

HY-146336

PARP1/2/TNKS1/2-IN-1	PARP Apoptosis	Cancer
PARP1/2/TNKS1/2-IN-1 (Compound I-9) is a dual *PARP-1, PARP-2*, TNKS1 and *TNKS2* inhibitor with IC₅₀ values of 0.25 nM, 1.2 nM, 13.5 nM and 4.15 nM against PARP-1, PARP-2, TNKS1 and TNKS2, respectively. PARP1/2/TNKS1/2-IN-1 exhibits favorable synergistic antitumor efficacy and induces apoptosis .

HY-10617D

Rucaparib acetate AG014699 acetate; PF-01367338 acetate	PARP	Cancer
Rucaparib (AG014699) acetate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib acetate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib acetate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617B

Rucaparib hydrochloride AG014699 hydrochloride; PF-01367338 hydrochloride	PARP	Cancer
Rucaparib (AG014699) hydrochloride is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib hydrochloride is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib hydrochloride has the potential for castration-resistant prostate cancer (CRPC) research .

HY-102003

Rucaparib monocamsylate Maximum Cited Publications 38 Publications Verification AG014699 monocamsylate; PF-01367338 monocamsylate	PARP	Cancer
Rucaparib (AG014699) monocamsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib monocamsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib monocamsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-102003A

Rucaparib camsylate AG014699 camsylate; PF-01367338 camsylate	PARP	Cancer
Rucaparib (AG014699) camsylate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib camsylate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib camsylate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-10617C

Rucaparib tartrate AG-014699 tartrate; PF-01367338 tartrate	PARP	Cancer
Rucaparib (AG014699) tartrate is an orally active, potent inhibitor of PARP proteins (PARP-1, PARP-2 and PARP-3) with a K_i of 1.4 nM for PARP1. Rucaparib tartrate is a modest hexose-6-phosphate dehydrogenase (H6PD) inhibitor. Rucaparib tartrate has the potential for castration-resistant prostate cancer (CRPC) research .

HY-157490

PARP/HDAC-IN-1	PARP HDAC	Cancer
PARP/HDAC-IN-1 (compound B102) is a potent dual inhibitor of PARP and HDAC. PARP/HDAC-IN-1 inhibits *PARP1, PARP2* and HDAC1 with IC₅₀s of 19.01, 2.13, 1690 nM, respectively .

HY-169299

TOPOI/PARP-1-IN-2	PARP Topoisomerase Apoptosis	Cancer
TOPOI/PARP-1-IN-2 (compound 6c) is a dual PARP-1 and topoisomerase 1 (TOPO-1) inhibitor with IC₅₀s of 32.2 nM and 46.2 nM, respectively. TOPOI/PARP-1-IN-2 shows a selectivity for PARP-1 over PARP-2. TOPOI/PARP-1-IN-2 disrupts the cell cycle at the S phase and induces apoptosis in NCI-60 cancer cell lines .

HY-12975

AZ6102 1 Publications Verification	PARP	Cancer
AZ6102 is a potent dual TNKS1 and TNKS2 inhibitor, with IC₅₀s of 3 nM and 1 nM, respectively, and alao has 100-fold selectivity against other PARP family enzymes, with IC₅₀s of 2.0 μM, 0.5 μM, and >3 μM, for PARP1, PARP2, and PARP6, respectively.

HY-157320

Tubulin/PARP-IN-2	Microtubule/Tubulin Apoptosis	Cancer
Tubulin/PARP-IN-2 (compound 14) is a dual PARP-Tubulin inhibitor. Tubulin/PARP-IN-2 inhibits PARP1, PARP2, and tubulin activity with IC₅₀ values of 74 nM, 109 nM, and 1.4 µM, respectively. Tubulin/PARP-IN-2 induces apoptosis as well as autophagy. Tubulin/PARP-IN-2 causes cell cycle arrest at the G2/M phase .

HY-133124

PARP/PI3K-IN-1	PARP PI3K Apoptosis	Cancer
PARP/PI3K-IN-1 (compound 15) is a potent PARP/PI3K inhibitor with pIC₅₀ values of 8.22, 8.44, 8.25, 6.54, 8.13, 6.08 for PARP-1, PARP-2, PI3Kα, PI3Kβ, PI3Kδ, and PI3Kγ, respectively. PARP/PI3K-IN-1 is a highly effective anticancer compound targeted against a wide range of oncologic diseases .

HY-100847

AZ0108	PARP	Cancer
AZ0108 is an inhibitor for poly ADP-ribose polymerase (PARP), which inhibits PARP1, PARP2, PARP3, PARP6, TNKS1, TNKS2, with IC₅₀s of <0.03, <0.03, 2.8, 0.083, 3.2, >3 μM, respectively. AZ0108 prevents centrosome clustering with an EC₅₀ of 0.053 μM, and exhibits cytotoxicity in cell OCI-LY-19 with GI₅₀ of 0.017 μM. AZ0108 exhibits good in vivo pharmacokinetic characters in rat/mouse models .

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Name
Email *

	Sorry, but the email address you supplied was invalid.

PARP-2/1-IN-2

Inhibitors & Agonists